Effectiveness of a novel multicomponent treatment in women with fibromyalgia: A randomized clinical trial.

IF 1.3 Q4 CLINICAL NEUROLOGY

British Journal of Pain Pub Date : 2024-10-18 DOI:10.1177/20494637241293760

Felipe Araya-Quintanilla, Celia Álvarez-Bueno, Iván Cavero-Redondo, Robinson Ramírez-Vélez, Walter Sepúlveda-Loyola, Héctor Gutiérrez-Espinoza

{"title":"Effectiveness of a novel multicomponent treatment in women with fibromyalgia: A randomized clinical trial.","authors":"Felipe Araya-Quintanilla, Celia Álvarez-Bueno, Iván Cavero-Redondo, Robinson Ramírez-Vélez, Walter Sepúlveda-Loyola, Héctor Gutiérrez-Espinoza","doi":"10.1177/20494637241293760","DOIUrl":null,"url":null,"abstract":"Background: Multicomponent treatment is commonly used. However, there are no studies that included graded motor imagery and therapeutic neuroscience education to multicomponent treatment for patients with fibromyalgia This study aims to compare the short-term effects (at 12 weeks) of a multicomponent treatment combined with graded motor imagery and therapeutic neuroscience education versus standard treatment in patients with FM.Methods: The study was a single-blinded randomized controlled trial. Sixty-five women with a clinical diagnosis of FM were randomly allocated (1:1) into two groups. The experimental group (n = 33) received a novel multicomponent treatment combined with graded motor imagery and neuroscience education. The control group (n = 32) received a standard treatment including pharmacotherapy and standard physician education. The primary outcome was pain intensity assessed with the Numeric Pain Rating Scale (NPRS). The secondary outcomes were changes in the Fibromyalgia Impact Questionnaire (FIQ), the Pain Catastrophizing Scale (PCS), the Tampa Scale of Kinesiophobia (TSK-17), and the Pittsburgh Sleep Quality Index (PSQI) scores. All outcomes were assessed at baseline and 12 weeks.Results: All of the participants completed the trial. The between-group mean differences at 12 weeks were: NPRS-1.18 points (95% confidence interval [CI] -0.4 to -1.8; η2 = 0.47; p < .001); FIQ-16.21 points (95% CI -10.9 to -22.1; η2 = 0.58; p < .001); PCS total domain -12.5 points (95% CI -7.2 to -17.8; η2 = 0.61; p < .001); TSK-17-6.15 points (95% CI -3.5 to -8.7; η2 = 0.52; p < .001); and PSQI-2.74 points (95% CI -1.4 to 4.0; η2 = 0.54; p < .001). All differences were statistically significant in favor of the novel multicomponent treatment group and had a large effect size.Conclusions: In the short term, a novel multicomponent treatment, including graded motor imagery and neuroscience education, was an effective therapeutic intervention for improving clinical outcomes compared with standard treatment in women with FM. Additional studies are needed to support long-term clinical effectiveness in these patients.","PeriodicalId":46585,"journal":{"name":"British Journal of Pain","volume":" ","pages":"20494637241293760"},"PeriodicalIF":1.3000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11559512/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pain","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20494637241293760","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Multicomponent treatment is commonly used. However, there are no studies that included graded motor imagery and therapeutic neuroscience education to multicomponent treatment for patients with fibromyalgia This study aims to compare the short-term effects (at 12 weeks) of a multicomponent treatment combined with graded motor imagery and therapeutic neuroscience education versus standard treatment in patients with FM.

Methods: The study was a single-blinded randomized controlled trial. Sixty-five women with a clinical diagnosis of FM were randomly allocated (1:1) into two groups. The experimental group (n = 33) received a novel multicomponent treatment combined with graded motor imagery and neuroscience education. The control group (n = 32) received a standard treatment including pharmacotherapy and standard physician education. The primary outcome was pain intensity assessed with the Numeric Pain Rating Scale (NPRS). The secondary outcomes were changes in the Fibromyalgia Impact Questionnaire (FIQ), the Pain Catastrophizing Scale (PCS), the Tampa Scale of Kinesiophobia (TSK-17), and the Pittsburgh Sleep Quality Index (PSQI) scores. All outcomes were assessed at baseline and 12 weeks.

Results: All of the participants completed the trial. The between-group mean differences at 12 weeks were: NPRS-1.18 points (95% confidence interval [CI] -0.4 to -1.8; η² = 0.47; p < .001); FIQ-16.21 points (95% CI -10.9 to -22.1; η² = 0.58; p < .001); PCS total domain -12.5 points (95% CI -7.2 to -17.8; η² = 0.61; p < .001); TSK-17-6.15 points (95% CI -3.5 to -8.7; η² = 0.52; p < .001); and PSQI-2.74 points (95% CI -1.4 to 4.0; η² = 0.54; p < .001). All differences were statistically significant in favor of the novel multicomponent treatment group and had a large effect size.

Conclusions: In the short term, a novel multicomponent treatment, including graded motor imagery and neuroscience education, was an effective therapeutic intervention for improving clinical outcomes compared with standard treatment in women with FM. Additional studies are needed to support long-term clinical effectiveness in these patients.

查看原文本刊更多论文

新型多成分疗法对纤维肌痛女性患者的疗效：随机临床试验。

背景：多成分治疗是常用的治疗方法。本研究旨在比较结合分级运动想象和治疗性神经科学教育的多组分疗法与标准疗法对纤维肌痛患者的短期疗效（12 周）：该研究是一项单盲随机对照试验。65名临床诊断为FM的妇女被随机分配（1:1）到两组。实验组（n = 33）接受新颖的多成分治疗，并结合分级运动想象和神经科学教育。对照组（n = 32）接受标准治疗，包括药物治疗和标准医生教育。主要研究结果是用数字疼痛评分量表（NPRS）评估疼痛强度。次要结果是纤维肌痛影响问卷 (FIQ)、疼痛灾难化量表 (PCS)、坦帕运动恐惧量表 (TSK-17) 和匹兹堡睡眠质量指数 (PSQI) 评分的变化。所有结果均在基线和 12 周时进行评估：所有参与者都完成了试验。12 周时的组间平均差异为NPRS-1.18分（95% 置信区间 [CI] -0.4至-1.8；η2 = 0.47；p < .001）；FIQ-16.21分（95% CI -10.9至-22.1；η2 = 0.58；p < .001）；PCS总域-12.5分 (95% CI -7.2 to -17.8; η2 = 0.61; p < .001)；TSK-17-6.15分 (95% CI -3.5 to -8.7; η2 = 0.52; p < .001)；PSQI-2.74分 (95% CI -1.4 to 4.0; η2 = 0.54; p < .001)。所有差异在统计学上都对新型多组分治疗组有显著影响，且影响程度大：结论：在短期内，与标准治疗相比，包括分级运动想象和神经科学教育在内的新型多成分治疗是一种有效的治疗干预措施，可改善女性 FM 患者的临床疗效。还需要更多的研究来支持这些患者的长期临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Pain CLINICAL NEUROLOGY-

CiteScore

3.20

自引率

11.10%

发文量

期刊介绍： British Journal of Pain is a peer-reviewed quarterly British journal with an international multidisciplinary Editorial Board. The journal publishes original research and reviews on all major aspects of pain and pain management. Reviews reflect the body of evidence of the topic and are suitable for a multidisciplinary readership. Where empirical evidence is lacking, the reviews reflect the generally held opinions of experts in the field. The Journal has broadened its scope and has become a forum for publishing primary research together with brief reports related to pain and pain interventions. Submissions from all over the world have been published and are welcome. Official journal of the British Pain Society.